Hamamatsu

Proscia Receives FDA 510(k) Clearance For Concentriq AP-Dx

Retrieved on: 
Monday, February 12, 2024
Marie Cassidy, Food and Drug Administration, FDA, Pathology, Food, Digital, European, Certification, Medicine, Patient, Hamamatsu, Laboratory, Pressure, Cancer

PHILADELPHIA, Feb. 12, 2024 /PRNewswire-PRWeb/ -- Proscia®, a leading provider of digital and computational pathology solutions, has received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA) for its Concentriq® AP-Dx*. The digital pathology solution was cleared for the purpose of primary diagnosis.

Key Points: 
  • PHILADELPHIA, Feb. 12, 2024 /PRNewswire-PRWeb/ -- Proscia® , a leading provider of digital and computational pathology solutions, has received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA) for its Concentriq® AP-Dx*.
  • Concentriq AP-Dx was designed to be used in clinical settings of all sizes, from individual reference laboratories to the largest hospital systems.
  • In support of its 510(k) clearance, Proscia conducted a multi-site clinical study at PathGroup, South Bend Medical Foundation, and Spectrum Healthcare Partners.
  • In addition to its 510(k) clearance, Proscia was the first company to achieve CE-IVDR certification to advance primary diagnosis in the European Union.

Agilent BioTek Cytation C10 Confocal Imaging Reader Enhanced with Innovative Water Immersion Technology

Retrieved on: 
Monday, December 4, 2023
Technology, Medical Devices, Medical Supplies, Genetics, Health Technology, Software, Biotechnology, Health, General Health, Hamamatsu, SCMOS, NYSE, Tissue, Immersion, Agilent Technologies, Marketing, C10, DSD, Atmosphere, Water, BioTek, CMOS, Microscope

Agilent Technologies Inc. (NYSE: A) today announced the addition of water immersion and new confocal spinning disk technology to the BioTek Cytation C10 confocal imaging reader .

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced the addition of water immersion and new confocal spinning disk technology to the BioTek Cytation C10 confocal imaging reader .
  • In light microscopy, water immersion technology automatically and consistently places a layer of water between the objective lens and the sample.
  • Spinning disk confocal technology improves microscopic images by blocking out-of-focus light from reaching the image sensor.
  • Additionally, integrating it with the Agilent BioTek BioSpa 8 automated incubator enables efficient multi-plate live-cell analysis.

Digital Pathology Market worth $1.8 billion | MarketsandMarkets

Retrieved on: 
Thursday, June 15, 2023
Prevalence, Marie Cassidy, Collaboration, Pathology, Investment, Hamamatsu, Digital pathology, Prohibition, Digital, Transport, Health, Software, Telepathology, FINANCIAL, Minerva Surgical, Inc. v. Hologic, Inc., Research, Danaher Corporation, Drug discovery, Diagnosis, Growth, US FDA, Data management, COVID-19, Cancer, Medicine, Biomarker, Algorithm, Porter's five forces analysis, Vail v. Juul Labs, Inc., Family, University, Sectra AB, Fujifilm, Benchmarking, Education, Health care, Medical imaging, Retail

Based on type, the digital pathology market is segmented into human pathology and veterinary pathology.

Key Points: 
  • Based on type, the digital pathology market is segmented into human pathology and veterinary pathology.
  • The human pathology segment accounted for the largest share of 66.5% of digital pathology type market in 2022.
  • The growing awareness of early cancer diagnosis in emerging economies, and increasing collaborations among academic research institutes, universities, and pathology laboratories drives the growth of the human pathology segment in the digital pathology market.
  • UPDATED MARKET DEVELOPMENTS OF PROFILED PLAYERS:
    Recent developments are important to understand the market trend and growth strategies adopted by players in the global digital pathology market space.

Digital Pathology Market worth $1.8 billion | MarketsandMarkets

Retrieved on: 
Thursday, June 15, 2023
Prevalence, Marie Cassidy, Collaboration, Pathology, Investment, Hamamatsu, Digital pathology, Prohibition, Digital, Transport, Health, Software, Telepathology, FINANCIAL, Minerva Surgical, Inc. v. Hologic, Inc., Research, Danaher Corporation, Drug discovery, Diagnosis, Growth, US FDA, Data management, COVID-19, Cancer, Medicine, Biomarker, Algorithm, Porter's five forces analysis, Vail v. Juul Labs, Inc., Family, University, Sectra AB, Fujifilm, Benchmarking, Education, Health care, Medical imaging, Retail

Based on type, the digital pathology market is segmented into human pathology and veterinary pathology.

Key Points: 
  • Based on type, the digital pathology market is segmented into human pathology and veterinary pathology.
  • The human pathology segment accounted for the largest share of 66.5% of digital pathology type market in 2022.
  • The growing awareness of early cancer diagnosis in emerging economies, and increasing collaborations among academic research institutes, universities, and pathology laboratories drives the growth of the human pathology segment in the digital pathology market.
  • UPDATED MARKET DEVELOPMENTS OF PROFILED PLAYERS:
    Recent developments are important to understand the market trend and growth strategies adopted by players in the global digital pathology market space.

Agilent Announces End-to-End Digital Pathology Workflow Solution at USCAP 2023

Retrieved on: 
Friday, March 10, 2023
Hardware, Electronic Design Automation, Health Technology, Consumer Electronics, Technology, Oncology, Professional Services, Artificial Intelligence, Science, Telecommunications, Software, Networks, Internet, Health, Research, Medicine, Senior, NYSE, Quest Diagnostics, Digital pathology, Quality control, Ohio State University, Partnership, Pathology, Prevalence, USCAP, Artificial intelligence, Digital, Hamamatsu, Marie Cassidy, Medical imaging, Medical device, Agilent Technologies

Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated end-to-end solution for digital pathology that brings together best-in-class products from Agilent , Visiopharm , Proscia® , and Hamamatsu Photonics K.K .

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated end-to-end solution for digital pathology that brings together best-in-class products from Agilent , Visiopharm , Proscia® , and Hamamatsu Photonics K.K .
  • Technological advances in the past decade and the numerous benefits of digital pathology are driving the practice to become widely adopted.
  • Agilent and Visiopharm have collaborated since 2020, developing an integrated solution comprising Visiopharm’s portfolio of leading artificial intelligence (AI)-driven precision pathology software and Agilent’s automated pathology staining solutions.
  • The technology combination of Agilent, Visiopharm, Proscia, and Hamamatsu strengthens the development of an open and agnostic end-to-end digital pathology solution with the vision of accelerating breakthroughs in precision medicine.

Agilent Announces Digital Pathology Scanner Distribution Agreement with Hamamatsu

Retrieved on: 
Friday, March 10, 2023
Biotechnology, General Health, Health Technology, Health, Hamamatsu Photonics, Medicine, NYSE, Agilent Technologies, Growth, Diagnosis, Patient, Pathology, Hamamatsu, Pressure, Workflow, FDA, Marie Cassidy, LIS, Medical imaging

, a leading provider of whole slide imaging systems, to incorporate their NanoZoomer range including the S360MD Slide scanner system into the Agilent end-to-end digital pathology solution.

Key Points: 
  • , a leading provider of whole slide imaging systems, to incorporate their NanoZoomer range including the S360MD Slide scanner system into the Agilent end-to-end digital pathology solution.
  • With the addition of the NanoZoomer Slide scanner systems, which converts glass slides into high-resolution digital data by high-speed scanning, Agilent completes its offering of an open and agnostic digital pathology workflow designed to accelerate breakthroughs in precision medicine.
  • “This distribution agreement strengthens Agilent’s open and agnostic end-to-end digital pathology offering and demonstrates our commitment to providing superior digital pathology solutions for our customers.”
    “Time is critical for patients and clinicians when awaiting a diagnosis.
  • At Hamamatsu, our NanoZoomer Slide scanner digital pathology product line will help revolutionize the diagnostic process, enabling fast turnaround times, more efficient workflows, and more collaboration among pathologists worldwide.

New FDSS-GX: the highest-performance kinetic plate imager in the FDSS series

Retrieved on: 
Wednesday, March 1, 2023
Luminescence, Injection, Hamamatsu, Drug discovery, Research, GPCR, Hamamatsu Photonics, Fluorescence, Television

BRIDGEWATER, N.J., March 1, 2023 /PRNewswire/ -- Hamamatsu Photonics announces the release of a new high-speed kinetic plate imager, the FDSS-GX, ideal for kinetic cell-based assay development, including GPCR / ion channel research and screening for drug discovery.

Key Points: 
  • BRIDGEWATER, N.J., March 1, 2023 /PRNewswire/ -- Hamamatsu Photonics announces the release of a new high-speed kinetic plate imager, the FDSS-GX, ideal for kinetic cell-based assay development, including GPCR / ion channel research and screening for drug discovery.
  • It offers a reliable and stable high-throughput screening, facilitating whole microplate imaging and simultaneous injections to all wells.
  • Its main benefits include a strong performance in terms of dispensing accuracy and repeatability when performing assays.
  • For more information about the FDSS-GX, including pricing and delivery time, please call Hamamatsu Corporation at (908) 231-0960 or visit the company's website, https://www.hamamatsu.com .

Energetiq Announces Business Unit Dedicated to EUV Light Sources

Retrieved on: 
Tuesday, December 13, 2022
R, EUV, McDaniel, Electrodeless lamp, Hamamatsu Photonics, Research, Hamamatsu, Growth, Multimedia, Engineering, Marketing, Management

WILMINGTON, Mass., Dec. 13, 2022 /PRNewswire/ -- Energetiq Technology, an innovative photonics manufacturer based in Wilmington, Massachusetts, announced today that it is creating a distinct business unit for its EUV light source products.

Key Points: 
  • WILMINGTON, Mass., Dec. 13, 2022 /PRNewswire/ -- Energetiq Technology, an innovative photonics manufacturer based in Wilmington, Massachusetts, announced today that it is creating a distinct business unit for its EUV light source products.
  • Energetiq's Electrodeless Z-Pinchextreme ultraviolet (EUV) light sources emit light in the key 13.5 nm region used in advanced node semiconductor metrology.
  • "Given the growth and importance of our EUV business to the semiconductor industry, we are pleased to develop an independent business unit to support our customers," said Debbie Gustafson, CEO of Energetiq.
  • The new EUV Business Unit will assemble all the core technology, engineering, marketing, field service, and operations personnel under the management of an EUV General Manager.

Indica Labs and Hamamatsu Photonics K.K. Announce Collaboration to Provide Optimized Integrated Digital Pathology Workflows

Retrieved on: 
Friday, October 14, 2022
Adoption, SDK, API, NHS trust, Efficiency, Review, Laboratory, Patient, Tissue, Multimedia, Artificial intelligence, Nottingham University Hospitals NHS Trust, Software, Industry, AI, European Economic Area, Hamamatsu, Glass, Research, United Kingdom, Hamamatsu Photonics, Trust, Anatomical pathology, NUH, JVCKenwood, HALO, Pathology, Solution, View, AP, Television, Medical imaging, Medical device, Indica

Indica Lab's browser-based, CE-marked* HALO AP software brings case-centric digital pathology slide management, collaboration, and AI-powered quantitative image analysis to Anatomic Pathology labs worldwide.

Key Points: 
  • Indica Lab's browser-based, CE-marked* HALO AP software brings case-centric digital pathology slide management, collaboration, and AI-powered quantitative image analysis to Anatomic Pathology labs worldwide.
  • This collaboration between Indica Labs and Hamamatsu streamlines this process.
  • Hamamatsu's technical collaboration with Indica Labs will facilitate Indica Labs approach to regulatory clearances utilizing the HALO AP system in conjunction with the NanoZoomer S360MD* for primary diagnosis.
  • The relationship between Indica Labs and Hamamatsu resulted in the win of significant digital pathology tenders in the United Kingdom, most notably Nottingham University Hospitals (NUH) NHS Trust.

Indica Labs and Hamamatsu Photonics K.K. Announce Collaboration to Provide Optimized Integrated Digital Pathology Workflows

Retrieved on: 
Friday, October 14, 2022
Adoption, SDK, API, NHS trust, Efficiency, Review, Laboratory, Patient, Tissue, Multimedia, Artificial intelligence, Nottingham University Hospitals NHS Trust, Software, Industry, AI, European Economic Area, Hamamatsu, Glass, Research, United Kingdom, Hamamatsu Photonics, Trust, Anatomical pathology, NUH, JVCKenwood, HALO, Pathology, Solution, View, AP, Television, Medical imaging, Medical device, Indica

Indica Lab's browser-based, CE-marked* HALO AP software brings case-centric digital pathology slide management, collaboration, and AI-powered quantitative image analysis to Anatomic Pathology labs worldwide.

Key Points: 
  • Indica Lab's browser-based, CE-marked* HALO AP software brings case-centric digital pathology slide management, collaboration, and AI-powered quantitative image analysis to Anatomic Pathology labs worldwide.
  • This collaboration between Indica Labs and Hamamatsu streamlines this process.
  • Hamamatsu's technical collaboration with Indica Labs will facilitate Indica Labs approach to regulatory clearances utilizing the HALO AP system in conjunction with the NanoZoomer S360MD* for primary diagnosis.
  • The relationship between Indica Labs and Hamamatsu resulted in the win of significant digital pathology tenders in the United Kingdom, most notably Nottingham University Hospitals (NUH) NHS Trust.